ESH 2016 - 3rd International Conference on Multiple Myeloma
7 - 9 Oct 2016
TBC, Milan, Italy
Outcome of multiple myeloma has dramatically improved over the last years with the introduction of novel agents. These agents have not only improved the complete remission rates, but they have resulted in tangible improvements in survival. At present, numerous questions surrounding the transplant and non-transplant settings remain, such as the role for prolonged/maintenance therapy, the role of high-dose therapy itself at the era of novel agents, as well as other practical questions regarding the optimization of the different steps of myeloma treatment algorithms. This educational meeting aims to address the latest developments in the field, as part of our quest for more effective and better-tolerated therapies, and improved understanding of the physiopathology of the disease. A large number of prestigious speakers will attend and deliver keynote lectures.
Upon completion of this CME activity, participants should be able to:
Acquire insight into the current diagnostic process of multiple myeloma, staging system, and risk stratification.
Evaluate the relevance of molecular diagnostics and minimal residual disease assessment, and their relevance for clinical management decisions.
Learn about treatment state of the art, and understand some of the critical clinical management issues in the treatment of young adults and patients of older age with fit or frail conditions.
Get insight into developmental therapeutics of multiple myeloma, Waldestrom macroglobulinemia and amyloidosis including knowledge about mechanisms of action of novel therapeutic compounds, the current status of development of various targeted drugs and their promises for future clinical applications.